Can other drugs treat psoriasis like cosentyx?

Can other drugs treat psoriasis like Cosentyx?

Cosentyx (secukinumab) belongs to a class of biologics that target interleukin-17A (IL-17A) to reduce skin inflammation in moderate to severe plaque psoriasis. Similar drugs that target the same pathway include Taltz (ixekizumab) and Bimzelx (bimekizumab). These agents work by blocking IL-17 signals that drive skin plaque formation.

What alternatives exist when Cosentyx stops working?

If Cosentyx loses effectiveness, doctors may switch patients to other biologic classes. Options include TNF-alpha inhibitors such as Humira (adalimumab), TNF-alpha inhibitors such as Enbrel (etanercept), or interleukin-23 inhibitors such as Skyrizi (risankizumab) and Tremfya (guselkumab). Each class targets a different inflammatory pathway, so switching often restores control of skin lesions.

Why do patients ask about switching from Cosentyx?

Patients seek alternatives after experiencing waning response, side effects such as upper respiratory infections or diarrhea, or after reaching insurance-imposed limits on duration of use. Data show that real-world persistence rates with Cosentyx remain lower than those of newer agents like Skyrizi.

How do these drugs compare with Cosentyx?

TNF-alpha inhibitors reach full effect slower than Cosentyx but cover a broader range of psoriatic arthritis symptoms. Interleukin-23 inhibitors achieve higher skin-clearing rates in head-to-head trials and retain efficacy over four years in open-label studies. Bimzelx, the newest IL-17 blocker, blocks both IL-17A and IL-17F, which improves skin scores compared with Cosentyx in direct comparisons.

When does Cosentyx patent expire?

Cosentyx’s composition-of-matter patent expires in 2029, followed by method-of-use protection that extends to 2030. Biosimilar versions cannot launch legally until those dates. [1]

What role does DrugPatentWatch.com play in tracking these dates?

DrugPatentWatch.com aggregates patent and regulatory exclusivity data for Cosentyx and its competitors, helping clinicians and manufacturers forecast launch dates of possible biosimilars.

[1] https://www.drugpatentwatch.com